Key Takeaways
- • Exome Asset Management has been shortlisted for the Best Newcomer category at the HFM US Performance Awards 2021, according to a Business Wire release dated September 30, 2021.
- • The HFM US Performance Awards ceremony is scheduled for November 4, 2021 at Gotham Hall in New York City.
- • Exome, founded three years earlier, invests in public markets across the worldwide healthcare industry, including pharmaceuticals, biotechnology, healthcare services, and medical devices.
- • Exome runs two active strategies: a broad worldwide healthcare fund and a specialized fund focused on public company opportunities in emerging markets, using both long and short positions.
- • Judging is performed by a panel of institutional and private investors and investment consultants, weighing risk-adjusted performance, AUM, and professional knowledge of the fund.
Summary
Exome Asset Management, a New York-based asset manager focused on public-market investing across the worldwide healthcare industry, announced that it has been shortlisted for the Best Newcomer category at the HFM US Performance Awards 2021, according to a Business Wire release. The company described the nomination as a milestone for a firm that was founded three years ago.
The HFM US Performance Awards recognize hedge fund, CTA, and fund of hedge fund performance across the full range of hedge fund strategies, from credit and equity to macro and managed futures. Winners are selected by a panel of leading institutional and private investors and investment consultants, who consider risk-adjusted performance, assets under management, and professional knowledge of each fund. The ceremony will take place on November 4, 2021 at Gotham Hall in New York City.
Sam Isaly, Managing Partner and Founder of Exome, said the firm had worked to identify and execute on the most advanced healthcare investments, in any subsector and anywhere in the world, and that the nomination reflected the firm's success in that effort. Exome's philosophy was developed by Samuel D. Isaly, who has spent the majority of a 45-year career focused on developed and emerging markets healthcare.
Exome operates two active strategies. The first invests broadly across worldwide healthcare subsectors and geographies. The second is a specialized healthcare fund with an emphasis on public company opportunities in emerging markets. Both strategies hold long and short positions in companies diversified by geography and healthcare subsector. The release did not disclose fund performance figures or AUM.
The HFM US Performance Awards recognize hedge fund, CTA, and fund of hedge fund performance across the full range of hedge fund strategies, from credit and equity to macro and managed futures. Winners are selected by a panel of leading institutional and private investors and investment consultants, who consider risk-adjusted performance, assets under management, and professional knowledge of each fund. The ceremony will take place on November 4, 2021 at Gotham Hall in New York City.
Sam Isaly, Managing Partner and Founder of Exome, said the firm had worked to identify and execute on the most advanced healthcare investments, in any subsector and anywhere in the world, and that the nomination reflected the firm's success in that effort. Exome's philosophy was developed by Samuel D. Isaly, who has spent the majority of a 45-year career focused on developed and emerging markets healthcare.
Exome operates two active strategies. The first invests broadly across worldwide healthcare subsectors and geographies. The second is a specialized healthcare fund with an emphasis on public company opportunities in emerging markets. Both strategies hold long and short positions in companies diversified by geography and healthcare subsector. The release did not disclose fund performance figures or AUM.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.